• Español
      • BPH Symptom Score

      Interventional BPH Education Program

      Take the first step in facilitating benign prostatic hyperplasia (BPH) management for your BPH patients.

      Contact us today to learn more about our Interventional BPH Education Program.

      Interventional BPH Education Program

      Contact Us

      BPH is the number one reason men visit a urologist,1 but the patient journey can be inefficient.

      li-check 53% of men with BPH never return for a second visit2 

      li-check 7-12% receive a diagnostic test2 

      li-check 65% of BPH patients are retained in Primary Care offices with limited options.3

      li-check Each year, more than 1/3 of BPH patients treated with medication discontinue treatment and are managed with watchful waiting4 

      li-checkOnly 2% of men seeing a doctor for BPH elect to have a surgical intervention5

      Graphic showing statistics for the BPH Market in the United States in 2022.

      For decades, treating BPH has meant making a difficult decision. Major surgery can provide adequate symptom relief but may have a longer recovery and higher risk of sexual dysfunction than minimally invasive treatments. Medications may provide marginal symptom relief but may have negative side effects and may include risk to long-term bladder health.

      Now you can change a patient’s journey with confidence with the UroLift™ System.

      • Provides rapid symptom relief6 and may eliminate the need for BPH medications.
      • Preserves sexual function*7 and may avoid prolonged recovery and discomfort.8† 
      • The #1 minimally invasive BPH procedure chosen by urologists and their patients in the U.S.5

      To learn more about how the UroLift™ System can benefit your hospitals and BPH patients, check the resources below.

      Cover for A Guide to Hospital Billing for the Prostatic Urethral Lift Procedure

      2023 Reimbursement Guide
      A graphic of the Hospital Resource Portal on a computer screen.

      Hospital Resource Portal

      Visit Now

      'Meet Mike' video

      *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study
       
      † Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older.
      As with any medical procedure, individual results may vary. Most common side effects are temporary and include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.6  Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult the Instructions for Use (IFU) for more information.
       
      1. IMS Health NDTI Urology Specialty Profile, July 2012 – June 2023; 2. PPS Analytics 2020 Data on file; 3. Figure based on raw, sample commercial and Medicare claims data available via Definitive Healthcare, as of March 2023, for this region. This does not represent projected data. “BPH Patients” are calculated as the sum of all BPH patients for whom BPH diagnosis claims have been submitted to identified insurance companies for the designated time period, and “BPH Claims” are calculated as the sum of all BPH diagnosis claims submitted to identified insurance companies for the designated time period. BPH diagnosis claims refer to the following codes: ICD 10 N400, N401, N402, N403, Cysto HCPCS 52000, intervention HCPCS 52441, 52442, 52647, 52648, 52649, 53584, 52601, 53852, 53850, 0421T. Rates shown are calculated as a percentage of claims vs the total. 4. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), data on file.; 5. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness.; 6. Roehrborn, J Urol 2013
      7. Roehrborn, Can J Urol 2017; 8. Shore, Can J Urol 2014
       
      Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

      Teleflex, the Teleflex logo, UroLift, and the UroLift logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.

      4155 Hopyard Road

      Pleasanton, CA 94588

      Phone: (925) 401-0700

      Fax: (925) 401-0699

      © 2024 Teleflex Incorporated. All rights reserved. MAC02660-01 Rev A    |    Terms of Use   |    Privacy Policy   |   Patient Safety


      MA00914-01 Rev C